Human medicines European public assessment report (EPAR): Lyumjev (previously Liumjev), insulin lispro, Date of authorisation: 24/03/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Liprolog, insulin lispro, Date of authorisation: 01/08/2001, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Humalog, insulin lispro, Date of authorisation: 30/04/1996, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Abasaglar (previously Abasria), insulin glargine, Date of authorisation: 09/09/2014, Revision: 13, Status: Authorised

Consolidated 3-year rolling work plan for the Methodology Working Party 2026-2028

Consolidated 3-year rolling work plan for the Non-clinical domain 2026-2028

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, Revision: 32, Status: Authorised

Clinical Trials Information System (CTIS): Walk-in clinic February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 February 2026, 16:00 (CET) to 18 February 2026, 17:00 (CET)

Product Management Service (PMS) – Frequently Asked Questions (FAQs)